The valuations available on China's booming Star Market are prompting US dollar managers to consider restructuring companies for onshore listings. How long will the fervor last?
What possesses a Chinese company – and its investors, if they get a say – to go to the trouble of dismantling an offshore structure with a view to pursuing an onshore IPO? Money, obviously. And right...
India’s Innoven Capital, a joint venture between UOB and Temasek Holdings-owned Seviora Holdings, has fractionalised a USD 50m venture debt fund using blockchain and smart contracts.
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.
Temasek Holdings, A91 Partners, and Kae Capital have invested USD 135m in Indian omnichannel wellness products retailer HealthKart.